SecSonar.com

Zai Lab Limited (ZLAB)

Zai Lab Limited at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Zai Lab Limited (ZLAB) is a Biotechnology company based in CN with a market capitalization of $2B. Revenue grew 15.3% year-over-year and free cash flow was negative at -$158.9M. This page tracks ZLAB's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

CN · 1.87K employees · IPO Sep 20, 2017

Valuation

Valuation & price

$20.59 · as of May 17, 2026 · -49.2% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

2.79

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$40.51$28.41$16.30Jul 25Dec 25Jul 26Jul 7, 25$35.48Jul 9, 25$35.66Jul 11, 25$32.73Jul 15, 25$35.19Jul 17, 25$36.01Jul 21, 25$34.66Jul 23, 25$37.37Jul 25, 25$37.17Jul 29, 25$40.51Jul 31, 25$37.80Aug 4, 25$38.05Aug 6, 25$38.72Aug 11, 25$34.66Aug 13, 25$35.63Aug 15, 25$35.73Aug 19, 25$35.44Aug 21, 25$33.99Aug 25, 25$34.03Aug 27, 25$32.56Aug 29, 25$33.10Sep 3, 25$31.30Sep 5, 25$30.76Sep 9, 25$31.49Sep 11, 25$32.48Sep 16, 25$32.30Sep 18, 25$33.00Sep 22, 25$33.15Sep 24, 25$32.49Sep 26, 25$31.62Sep 30, 25$33.89Oct 2, 25$33.85Oct 6, 25$33.31Oct 8, 25$33.69Oct 10, 25$30.24Oct 14, 25$29.40Oct 16, 25$28.84Oct 21, 25$29.15Oct 23, 25$28.02Oct 27, 25$26.34Oct 29, 25$25.32Oct 31, 25$26.13Nov 4, 25$25.89Nov 6, 25$23.15Nov 10, 25$21.89Nov 12, 25$21.88Nov 14, 25$21.75Nov 18, 25$20.48Nov 20, 25$20.21Nov 25, 25$19.90Nov 28, 25$20.41Dec 2, 25$19.52Dec 4, 25$19.95Dec 8, 25$19.05Dec 10, 25$18.28Dec 12, 25$17.77Dec 16, 25$17.00Dec 18, 25$17.18Dec 22, 25$17.71Dec 24, 25$18.58Dec 29, 25$17.82Jan 2, 26$17.33Jan 6, 26$18.20Jan 8, 26$18.50Jan 12, 26$18.39Jan 14, 26$19.61Jan 16, 26$18.58Jan 21, 26$18.84Jan 23, 26$18.33Jan 27, 26$17.05Jan 29, 26$17.25Feb 2, 26$16.30Feb 4, 26$17.00Feb 9, 26$18.44Feb 11, 26$19.03Feb 13, 26$20.03Feb 18, 26$20.18Feb 20, 26$20.04Feb 24, 26$19.37Feb 26, 26$19.69Mar 2, 26$18.42Mar 4, 26$19.27Mar 6, 26$19.54Mar 10, 26$19.46Mar 12, 26$18.87Mar 17, 26$19.02Mar 19, 26$18.61Mar 23, 26$17.61Mar 25, 26$18.29Mar 27, 26$18.00Mar 31, 26$18.81Apr 2, 26$20.41Apr 7, 26$21.00Apr 9, 26$20.74Apr 13, 26$21.34Apr 15, 26$23.25Apr 17, 26$24.19Apr 22, 26$22.87Apr 24, 26$22.77Apr 28, 26$22.14Apr 30, 26$21.64May 4, 26$21.22May 6, 26$21.01May 8, 26$18.60May 12, 26$19.53May 14, 26$20.33May 18, 26$18.86May 20, 26$18.81May 22, 26$18.61May 28, 26$18.48Jun 1, 26$17.09Jun 3, 26$17.17Jun 5, 26$16.62Jun 9, 26$16.65Jun 11, 26$17.64Jun 15, 26$17.73Jun 17, 26$17.88Jun 22, 26$18.48Jun 24, 26$18.37Jun 26, 26$18.00Jul 2, 26$19.12
$16.3052-week range$40.51
Loading valuation history…

Fundamentals

Key fundamentals

$2B

Market cap

15.3%

Revenue growth (YoY)

58.5%

Gross margin

-$158.9M

Free cash flow (USD)

-$465.3M

Net debt

Net cash position

10.7%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$0.00FY 2017$0.00FY 2018$129.5KFY 2019$13.0MFY 2020$49.0MFY 2021$144.3MFY 2022$215.0MFY 2023$266.7MFY 2024$399.0MFY 2025$460.2M
$0$460.2M

Free cash flow by year

2016 → 2025

FY 2016$-34.4MFY 2017$-41.5MFY 2018$-107.7MFY 2019$-206.3MFY 2020$-226.7MFY 2021$-568.2MFY 2022$-392.6MFY 2023$-206.7MFY 2024$-276.4MFY 2025$-158.9M
-$34.4M-$158.9M

Gross margin by year

2021 → 2025

FY 202163.8%FY 202265.6%FY 202364.1%FY 202462.9%FY 202558.5%
63.8%58.5%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

13

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $130KDu Ying · Director, Chairperson & CEO · $130.2KJul 1, 2026Filing
  • Insider sellInsider Sell $40KChen Yajing · Chief Financial Officer · $39.5KJun 29, 2026Filing
  • Insider sellInsider Sell $429KDu Ying · Director, Chairperson & CEO · $428.5KJun 29, 2026Filing
  • Insider sellInsider Sell $72KEdmondson Frazor Titus III · Chief Legal Officer · $71.6KJun 29, 2026Filing
  • Insider sellInsider Sell $127K · 10b5-1 PlanLis William · Director · $127.4KJun 24, 2026Filing
  • 8-K eventAnnual General Meeting ResultsJun 17, 2026Filing
  • 8-K eventExecutive DepartureMay 21, 2026Filing
  • Insider sellInsider Sell $2.0M · 10b5-1 PlanDu Ying · Director, Chairperson & CEO · $2MMay 19, 2026Filing
  • Insider sellInsider Sell $2.0M · 10b5-1 PlanDu Ying · Director, Chairperson & CEO · $2MMay 15, 2026Filing
  • Insider sellInsider Sell $71K · 10b5-1 PlanEdmondson Frazor Titus III · Chief Legal Officer · $71KMay 15, 2026Filing

Questions

Frequently asked questions

What is Zai Lab Limited's market cap?

Zai Lab Limited (ZLAB) has a market capitalization of $2B.

What is ZLAB's P/E ratio?

A meaningful P/E ratio is not available for ZLAB — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is ZLAB's price-to-book (P/B) ratio?

ZLAB trades at 2.79 times book value per share.

Are insiders buying ZLAB stock?

SEC Form 4 filings show no open-market insider buys at Zai Lab Limited in the last 90 days (13 sells).

Same arena

Related companies in Biotechnology

MESO

Mesoblast Limited

$2B

OCUL

Ocular Therapeutix, Inc.

$2B

NBTX

Nanobiotix S.A.

$2B

AUPH

Aurinia Pharmaceuticals Inc.

$2B

STOK

Stoke Therapeutics, Inc.

$1.9B

SRPT

Sarepta Therapeutics, Inc.

$1.9B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.